Ways2Capital Reviews : Syngene International Signs Partnership With Artelo Biosciences

Syngene International has entered into a global R&D partnership with a biopharma company Artelo Biosciences. This partnership will focus on supporting the drug discovery and clinical development of ART27.13, Artelo's Phase 2 ready, high-potency dual cannabinoid agonist, in oncology.

As a part of this agreement, Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications.

As per Syngene, oncology is one of its focus areas and this partnership helps in harnessing its expertise to develop a better product for the benefit of cancer patients worldwide.

Artelo Biosciences is US headquartered small Bio pharma company, which has currently three molecules in the pipeline. ART27.13 is its lead molecule, while two other molecules ART 12.11 and ART26.12 are in early discovery stage.
In May 2018, Syngene announced that it has entered in a partnership with Zumutor Biologics for Biotherapeutic antibody services.
For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai